Compare 10X Genomics Inc (TXG) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Weibo Corp — how do they compare? 10X Genomics Inc trades at $47.2 (market cap $5.48B), while Weibo Corp trades at $8 (market cap $1.95B). The key difference: 10X Genomics Inc is far larger — about 2.8× Weibo Corp's market cap, and Weibo Corp pays a 7.63% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TXG | WB | |
|---|---|---|
Market Cap | $5.48B | $1.95B |
Sector | Health | Media |
52-Week High | $45.80 | $12.83 |
52-Week Low | $11.34 | $7.20 |
Enterprise Value | $5.02B | $1.22B |
Dividend Yield | — | 7.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Weibo (WB) trades at $8.00, up 3.23% today, with a bullish technical signal from moving averages. The stock shows strong profitability with a 21.15% net income margin and trades at discounted valuations including a P/E of 5.59 and P/B of 0.51. Recent earnings missed expectations for three consecutive quarters, but the company maintains robust cash flow generation and a solid balance sheet with $2.35 billion in cash.
The outlook is mixed: deep value metrics and analyst buy ratings (45%) support upside potential, but competitive pressures and recent earnings misses pose risks. The stock's 8% dividend yield provides income support while investors await improved execution and AI monetization opportunities to drive growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
